Mesa Laboratories Inc: Form 10-K for the period ended Mar 31, 2021
Filed with the SEC on Jun 1, 2021 and accepted by EDGAR at Jun 1, 2021, 11:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $38.0m | us-gaap:Revenues |
| Revenue | 12 months2020-04-01 to 2021-03-31 | $133.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2020-04-01 to 2021-03-31 | $46.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $24.7m | us-gaap:GrossProfit |
| Gross profit | 12 months2020-04-01 to 2021-03-31 | $87.0m | us-gaap:GrossProfit |
| Research and development | 12 months2020-04-01 to 2021-03-31 | $10.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2020-04-01 to 2021-03-31 | $12.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2020-04-01 to 2021-03-31 | $8.0m | us-gaap:InterestExpense |
| Income tax | 12 months2020-04-01 to 2021-03-31 | −$971.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-03-31 | $3.9m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | $0.74 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2020-04-01 to 2021-03-31 | $0.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | $0.76 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2020-04-01 to 2021-03-31 | $0.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2020-04-01 to 2021-03-31 | 5,124,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2020-04-01 to 2021-03-31 | $37.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-04-01 to 2021-03-31 | $2.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2020-04-01 to 2021-03-31 | $3.2m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-03-31 | $263.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $303.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $601.5m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $32.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $195.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-03-31 | $406.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-21-013801. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.